Crofelemer Patent Expiration
Crofelemer is Used for providing symptomatic relief for non-infectious diarrhea. It was first introduced by Napo Pharmaceuticals Inc
Crofelemer Patents
Given below is the list of patents protecting Crofelemer, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Mytesi | US8962680 | Methods and compositions for treating HIV-associated diarrhea | Oct 31, 2031 | Napo Pharms Inc |
| Mytesi | US9585868 | Methods and compositions for treating HIV-associated diarrhea | Oct 31, 2031 | Napo Pharms Inc |
| Mytesi | US7341744 | Method of treating secretory diarrhea with enteric formulations of proanthocyanidin polymer |
Jun 16, 2018
(Expired) | Napo Pharms Inc |
| Mytesi | US7323195 | Enteric formulations of proanthocyanidin polymer antidiarrheal compositions |
Jun 07, 2018
(Expired) | Napo Pharms Inc |
| Mytesi | US8574634 | Compositions and methods of treatment with proanthocyanidin polymer antidiarrheal compositions |
Jan 11, 2018
(Expired) | Napo Pharms Inc |
About Veterinary Crofelemer
Crofelemer is used in a drug marketed by 1 company: Jaguar Animal Health.
Other drugs containing Crofelemer are: Canalevia ca1 .
Crofelemer's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Crofelemer:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Ascending Doses of Crofelemer Powder for Oral Solution in Pediatric Microvillus Inclusion Disease (MVID) | Napo Pharmaceuticals, Inc. | NA |
ACTIVE NOT RECRUITING
(Jun 1, 2026)
| PHASE2, PHASE3 |
| Safety and Efficacy of Crofelemer in Adult Patients With Short Bowel Syndrome and Intestinal Failure (SBS-IF) Without Colon-in-continuity (CIC) | Napo Therapeutics, S.p.A. | NA |
RECRUITING
(May 1, 2026)
| PHASE2 |